New Zealand has approved two psychiatrists to prescribe pharmaceutical-grade MDMA for adults with severe post-traumatic stress disorder (PTSD), becoming the second country after Australia to permit the therapy. The treatment will combine controlled MDMA use with psychotherapy and will only be provided in clinical settings under medical supervision.
New Zealand's medicines regulator has approved two psychiatrists to prescribe pharmaceutical-grade MDMA to people with severe post-traumatic stress disorder (PTSD), making the country only the second in the world to allow the drug for treating the condition.
The approval by New Zealand's pharmaceutical regulatory body, Medsafe, follows Australia's decision in 2023 to permit the use of psychedelics for treating PTSD and treatment-resistant depression, The Guardian reports.
“PTSD ruins lives and is difficult to treat,” said Deputy Prime Minister David Seymour, who last year backed the approval of magic mushrooms to treat people with severe depression. “MDMA can be very effective at treating it through psychedelic-assisted therapy.”
Seymour said New Zealand was committed to expanding access to “innovative treatments”.
-
Kuwait Rescue: Tamil Nadu Woman Gets Embassy Help After Desperate SOS
-
Bengal native arrested in Hyderabad with 91 gram heroin
-
Renowned Islamic scholar Abdul Hannan Siddiqui passes away
-
Govt bus fares set for revision in Karnataka amid rising losses
-
Bengaluru jail inmates attack warder, attempt to kill him
